Loading...
Market
What type of software will Neuralink's second patient, Alex, control next by end of 2024?
2
Resolution / Starting Odds
Productivity Software • 25%
Entertainment Software • 25%
Educational Software • 25%
Other • 25%
Neuralink official reports or press releases
Story
Neuralink's Second Patient Uses Implant to Play Counter-Strike 2 and Design with Fusion 360
Aug 21, 2024, 10:55 PM
Neuralink has successfully implanted its brain chip into a second human participant, Alex, as part of its PRIME Study. The surgery was conducted at the Barrow Neurological Institute, and Alex was discharged the following day with a smooth recovery. The implant allows Alex to control digital devices using his thoughts, enabling him to play video games like Counter-Strike 2 and use computer-aided design (CAD) software, including Fusion 360. Neuralink has reported no issues with thread retraction, a problem that affected the first patient. Alex expressed his satisfaction with the technology, noting its impressive functionality. Remarkably, Alex broke the previous BCI Webgrid record on his first day.
View original story
Similar markets
Yes • 50%
No • 50%
Breaks another BCI Webgrid record • 25%
Wins a Counter-Strike 2 tournament • 25%
Designs a complex 3D object using CAD software • 25%
Other • 25%
Yes • 50%
No • 50%
Medical rehabilitation • 25%
Gaming and entertainment • 25%
Industrial and design applications • 25%
Other • 25%
Yes • 50%
No • 50%
Very Satisfied • 25%
Satisfied • 25%
Neutral • 25%
Dissatisfied • 25%
Successful with no issues • 25%
Successful with minor issues • 25%
Unsuccessful due to technical issues • 25%
Unsuccessful due to patient complications • 25%
Telepathic communication • 25%
Enhanced cognitive functions • 25%
Control of robotic limbs • 25%
Curing paralysis • 25%
New regulatory approval • 25%
New patient milestone • 25%
Commercial availability plans • 25%
New technological breakthrough • 25%
Assistive technology for paralysis • 25%
Cognitive enhancement • 25%
Medical treatment for neurological disorders • 25%
Other • 25%
Restoring eyesight to a blind individual • 25%
Enhancing vision for partially sighted individuals • 25%
Other medical applications • 25%
No application by end of 2024 • 25%